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Methylphenidate (MPH) is a stimulant that increases extracellular levels of dopamine and noradrenaline. It can diminish risky decision-
making tendencies in certain clinical populations. MPH is also used, without license, by healthy adults, but the impact on their decision-
making is not well established. Previous work has found that dopamine receptor activity of healthy adults canmodulate the influence of
stake magnitude on decisions to persistently gamble after incurring a loss. In this study, we tested for modulation of this effect by MPH
in 40 healthy human adults. In a double-blind experiment, 20 subjects received 20 mg of MPH, while 20 matched controls received a
placebo. All were provided with 30 rounds of opportunities to accept an incurred loss from their assets or opt for a “double-or-nothing”
gamble that would either avoid or double it. Rounds began with a variable loss that would double with every failed gamble until it was
accepted, recovered, or reached a specifiedmaximum. Probability of recovery on any gamble was low and ambiguous. Subjects receiving
placebo gambled less as themagnitude of the stake was raised and as themagnitude of accumulated loss escalated over the course of the
task. In contrast, subjects treated with MPH gambled at a consistent rate, well above chance, across all stakes and trials. Trait reward
responsiveness also reduced the impact of high stakes. The findings suggest that elevated catecholamine activity by MPH can disrupt
inhibitory influences on persistent risky choice in healthy adults.
Introduction
How does one know when to quit? Persisting with uncertainty
can make up for lost investment, but it can also make matters
worse.With this paper, we examine the effect of the psychostimu-
lant methylphenidate (MPH; Ritalin) on the influence of cues to
inhibit persistent risky choice.
MPH increases extracellular levels of dopamine and nor-
adrenaline (Volkow et al., 2001; Berridge et al., 2006; Gamo et al.,
2010). It is also an established treatment of attention deficit hy-
peractivity disorder (Wilens, 2008). In various clinical contexts,
MPH can bring certain risky decision-making tendencies closer
to those of untreated healthy individuals (Rahman et al., 2006;
DeVito et al., 2008; Shiels et al., 2009). However, MPH is also
increasingly used as a so-called “smart pill” by healthy adults
(Smith and Farah, 2011), for which its effects on risky decision
making are not well established. The beneficial effects of MPH
likely depend on baseline catecholamine activity and optimal
neuromodulation for a particular cognition (Cools et al., 2001;
Clatworthy et al., 2009; Robbins and Arnsten, 2009). Despite
normalizing clinical effects,MPH could detrimentally affect risky
decision making of individuals without catecholamine deficits.
There is good evidence to suggest this would be the case. First,
MPH can increase affective and neural responses to reward in
healthy adults (Volkow et al., 2002, 2004), which is presumably in-
dicative of enhanced estimates of reward utility. Second, MPHmay
alter estimates of probability. Among its pharmacological effects,
MPH indirectly increases D2 andD3 receptor binding in the healthy
human striatum (Volkow et al., 2001; Clatworthy et al., 2009). In
Parkinson’spatients, direct activationofD2/D3 receptorsby agonists
can inhibit learning about low outcome probability due, theoreti-
cally, to masked expression of midbrain dopamine fluctuations
(Frank et al., 2004; Cools et al., 2006). D2/D3 agonists are also asso-
ciated with pathological gambling onset, which inherently involves
an increase of risky decision making when it is seemingly unwise to
do so (Weintraub et al., 2010). In healthy adults, direct D2/D3 acti-
vationalters the inhibiting influenceof stake sizeondecisions to take
double-or-nothing risks after experiencing loss (Campbell-
Meiklejohn et al., 2011).
Double-or-nothinggambles set themagnitudeofpotential gainand
themagnitudeofpotential losstothemagnitudeofthecumulativeprior
loss. These are risky opportunities for complete loss recovery.
High stakes can reduce tendencies to accept risks (Binswanger,
1981; Holt and Laury, 2002, 2005). This effect, however, may be
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offset by increased reward incentive or by overestimation of re-
ward probability. As discussed above, both are potential effects of
MPH. We tested whether MPH, like direct D2/D3 receptor ago-
nists, would diminish the effect of high stakes to take double-or-
nothing risks in healthy adults. To investigate the potential role of
higher affective responses to reward, we tested whether high trait
reward responsiveness would have a similar effect.
Materials andMethods
The ethics committee of Central Jutland Region, Denmark, approved the
study, and all subjects gave written informed consent.
Screening
Subjects were given a physical examination by a physician and screened
with the Structured Clinical Interview for Diagnostic and Statistical
Manual of Mental Disorders, 4th edition (DSM-IV) Axis I disorders to
ensure that none of the following exclusion criteria were met: (1) major
physical illness, head trauma or pregnancy; (2) use of psychotropicmedica-
tion in the previous 3 months; (3) current or previous DSM-IV anxiety or
mooddisorder; (4) current or previousDSM-IVpsychotic disorder; and (5)
current or previousDSM-IV substance use disorder. Subjects were screened
for pathological gambling with the South Oaks Gambling Screen (Lesieur
and Blume, 1987). There was no evidence of a problem or pathological
gambling. Use of hormonal contraception was not an exclusion criterion.
Trait measures
After screening, we recorded trait measures of anxiety [Spielberger State-
TraitAnxiety Index (STAI)] (Spielberger, 1970), gambling-relatedcognition
(Gambling Related Cognition Scale) (Raylu and Oei, 2004), self-reported
chasing tendency (O’Connor and Dickerson, 2003), Behavioral Inhibition
System-Behavioral Activation System Scales (BIS-BAS) (Carver andWhite,
1994), intelligence quotient (IQ) (Wechsler, 2005), andmood [Positive and
Negative Affect Scale (PANAS)] (Watson et al., 1988). The BIS-BAS con-
tained the following four subscales: behavioral inhibition (BIS), reward re-
sponsiveness (BAS-R), drive (BAS-D), and fun-seeking (BAS-F).
Group assignment
Forty healthy adults (all female) were accepted to the study. From these
volunteers, 20 pairs were formed,matched on age (mean 23 years, SD 2.8
years) years of education (mean 13.8, SD1.8), performance IQ [Wechsler
Adult Intelligence Scale III (WAIS-III Matrix Reasoning, scaled; mean
12.8, SD 1.8), and verbal IQ (WAIS-III Vocabulary, scaled; mean 11.5,
SD 1.9). One subject of each pair was randomly allocated to a drug group,
MPH or placebo, with a double-blind procedure.
State measures
On arrival at the laboratory, subjects completed baseline assessments of
state anxiety (STAI) and mood (PANAS). These were assessed again at
estimated peak MPH absorption and immediately before cognitive test-
ing. Changes from before to after drug absorption were calculated for
each measure. Side effects of nausea and headache were assessed just
before testing as a self-reported rating from 0 (not at all) to 7 (severe).
Drug administration
All subjects were tested within the first 12 d of their menstrual cycle and
were asked to refrain from caffeine for 24 h before the study. Subjects
received either MPH (2 10 mg) or placebo at 11:00 A.M. on test day,
1.5 h before behavioral testing.
The loss-chasing task
Named for the decision to “chase” losses (gambling to recover them)
(Lesieur, 1984; O’Connor and Dickerson, 2003), variations of this task
have been described previously (Campbell-Meiklejohn et al., 2008, 2011;
Rogers et al., 2011). In this experiment, we implemented a fixed proba-
bility of winning on any trial, randomized the initial stake presented, and
limited the task to 30 rounds. Feedback was translated to Danish, and
Danish currency was used.
Reward structure. At the start of the game, subjects were told that they
had a fictional 192,000 Danish kroner (kr) (U.S. $35,000) in total assets
and that the subject who loses the least fictional money during the game
would receive a real prize of 500 kr (U.S. $88). Subjects were not told how
others had performed, so all they could do was try to achieve the best
score that they could. Mixtures of nominal and actual rewards such as
this have been used in behavioral economics to produce behavior quali-
tatively and quantitatively similar to that observed outside the laboratory
(Cubitt et al., 1998). Positive outcomes with this payoff structure signif-
icantly activate brain regions associated with primary and financial re-
wards (Campbell-Meiklejohn et al., 2008).
Rounds and trials. The game (Fig. 1) consisted of 30 “rounds.” Each
round consisted of one to six “trials.” Each trial followed a loss. The first
trial of a round began with an imposed loss of 100, 200, 400, 800, or 1600
kr, chosen at random. The round loss appeared below two choices:
“Quit” and “Play.” This value was also the amount that could be gained
or lost by choosing Play (i.e., chasing the loss). We call this amount the
“stake.” If the gamble’s outcome was positive, the stake was won, prior
round losses were recovered, and the round ended. If the outcome was
negative, the stake was lost and added to prior round losses (i.e., the
round loss doubled), and subjects were given another double-or-nothing
opportunity to fully recover round losses on the next trial of the round.
This continued until a maximum round loss of 6400 kr was reached. If
this maximumwas reached, the round ended and 6400 kr was subtracted
from the subject’s total assets. ChoosingQuit subtracted the round losses
up to that point from the subject’s assets and ended the round immedi-
ately. Due to the random starting stake of rounds, the number of losses
preceding a trial in a round (one to six) and the analyzed stake sizes (see
Statistical Analysis) shared only 9% of their variance.
Probability of winning. A total of 15% of Play choices would result in a
reward. The probability of winning on one trial was independent of the
probability of winning on others. This means that the probability of
recovering losses of a roundwould range from 30 to 90% (with two to six
trials), if every choice were to play, depending on the starting stake of a
round. Subjects, however, were not told these probabilities. Decisions
were made with ambiguous uncertainty.
Dependent variables. The main dependent measure of interest was the
decision to gamble (1 Play, 0Quit). The number and proportion of
decisions to switch choices from the previous trial were also measured.
For comparison to a previous study (Campbell-Meiklejohn et al., 2011),
we also measured overall play ratios (choices to play/all choices), chase
value ratios (mean stake of choices to play/overallmean stake), quit value
ratio (mean stake of choices to quit/overall mean stake), and deliberation
time.
Independent variables.Within-subject predictors of interest were stake
size and accumulated losses (from all rounds). Between-subject predic-
tors were drug group (MPH 1, placebo1), and independently, spe-
cific BIS/BAS personality measures.
Strategy. To encourage deliberation on each trial, subjects were in-
formed (correctly) that they would not achieve the best possible score by
exclusively playing or quitting. However, subjects were still free to use
these strategies, and there was no penalty for doing so. No information
was provided about overall accumulated game losses during the task.
Statistical analysis
Between-group comparisons were performed by independent sample t
test or appropriate non-parametric analysis (e.g., Welch’s t test for un-
equal variances), using SPSS 19 (IBM) (Field, 2009). Relationships of
predictors to choices were assessed by multilevel mixed logistic regres-
sions. Relationships of predictors to reaction times were assessed bymul-
tilevelmixed linear regression. The slope and intercept of the relationship
between within-subject predictors and dependent measures were al-
lowed to vary, as random effects, between subjects. Between-subject pre-
dictors were treated as fixed effects. Modeling of correlation parameters
for random effects was determined using likelihood ratio testing. If no
difference was observed, the more parsimonious (uncorrelated) model
was used. All continuous variables were mean corrected. Regressions
were performed in R (R Development Core Team) using the lme4 linear
mixed model package for R (Bates and Maechler, 2009). Parameter esti-
mates, SE of estimate, test statistics (t or z, p), and SD of random effects
(SDRE) of regressions are reported in tables. Correlations between mea-
sures were tested with Pearson correlation coefficients.
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Demographic, trait, and state measures. To ensure that group effects on
task behavior were not due to differences of demographic, trait, or state
measures, these variables were compared between groups and tested for
correlation to behavioral measures if differences were significant.
Task reinforcement. To ensure groups experienced similar stakes and
reinforcement during the task, between-group comparisons were used to
test for differences of mean (1) win frequency, (2) win magnitude, (3)
losses in a round before a win, and (4) initial round loss.
Choice. Overall play ratio was compared, between groups and within
each group, to chance (0.5). Number and proportion of decisions to
switch from the previous choice were also compared between groups.
The effect of stake. For investigations of stake size influence, we only
analyzed choices at stakes that were (1) presentedwith equal frequency in
both drug groups (3200 kr was not) and (2) presented frequently enough
to generate meaningful play ratio statistics (100 kr was not). We used a
multilevel mixed logistic regression that modeled the intercept and stake
(in 100 kr units) magnitude as uncorrelated random effects, and two
fixed effects: drug group (MPH1, placebo1); and drug group
stake interaction.When a drug group stake interactionwas confirmed,
we investigated further by a separate random-effects analysis of stake
effects in each drug group. We then compared play ratios at each indi-
vidual stake between groups. To test for the stake group effect without
the first trial of the round (limiting chasing to losses caused by the gam-
bling), we repeated the main regression on this limited dataset.
The effect of accumulated loss. To estimate the effect of accumulated
loss (all rounds) on the choice to Play or Quit, we performed amultilevel
mixed logistic regression containing the intercept and accumulated loss
(in 1000 kr units) as uncorrelated random effects, and two fixed effects
[drug group (MPH1, placebo1) and its interaction with accu-
mulated loss].When an interaction effect was confirmed, we investigated
further by a separate random-effects analysis of accumulated loss effects
in each drug group.
BIS/BAS. To investigate the role of affective responses to reward and
other reward-related processes on stake effects, reward responsiveness
(BAS-R), fun-seeking (BAS-F), and drive (BAS-D) were each tested as
between-subject predictors of the effect of stake on choice. Multilevel
mixed logistic regression models included the intercept and stake as un-
correlated random effects, and two fixed effect parameters: the respective
BIS/BAS subscore and its interaction with stake. An identical modeling
procedure was used to investigate the effect of BIS/BAS trait interactions
with accumulated loss on choice.
Deliberation time. Mean deliberation time was compared between
groups and between decisions. We modeled the influence of stake on
deliberation time with a multilevel mixed linear regression. The
model included correlated random effects of intercept and stake, and
fixed effects of drug group and its interaction with stake. Significance
tests of fixed effect parameters were conducted as likelihood ratio
tests between nested models, with and without the examined param-
eter. To test for an effect of accumulated losses on deliberation time,
we performed an identical regression with accumulated loss, in the
place of stake.
Results
Demographic, trait, and state measures
Two subjects (bothMPH) from the group of 40 reported a severe
headache (score 5 of 7) just before performing the task. We
removed these subjects from subsequent analysis. We also re-
moved one MPH subject with an outlier BAS-D score (2 SDs
above the overall mean), which is known to predict positive af-
fective responses to reward anticipation (Carver and White,
1994) and may have generated a false-positive result. In the re-
maining dataset, trait anxiety differed slightly between groups
(placebo 29 5 (SD); MPH 26 4; t(35) 2.1, p 0.04) but did
not correlate with any behavioral measure (p values 0.38).
Groups were equal on all other state and trait measures (p
values 0.15).
Figure 1. The options for each choice—Play or Quit—appeared randomly on the left and right side of the computer display during the decision phase. Each round began with a loss (also the
stake) displayed for 3 s. This was followed by a choice to accept that loss (Quit) and end the round or to risk the value of the loss (Play) to try and recover it. Subjects responded by pressing keys on
a mouse corresponding to the side of their desired choice. Choices were randomly assigned to sides of the display from round to round. Outcome displays (2 s) indicated whether subjects had won
a gamble and that no money was lost (Play &Win); whether they had lost a gamble and the amount lost (Play & Lose); or the amount lost from assets if subjects chose to give up (Quit). If the loss
reached6400 kr, the roundautomatically endedwithno chance of recovery (Play&LoseMax). At the endof each round, subjectswere informedof the amount thatwouldbe takenoff their final total
as a result of that round. Therewasno time limit formakingadecision. Thedotted line indicates the subject’s choice butwasnot displayed to subjects.Wordswere translated toDanish. Displayswere
presented to subjects in color with losses, negative outcomes, and Quit displays indicated in red font. Positive outcomes were indicated in green.
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Task reinforcement
The groups experienced equal mean (1) win frequency [MPH
7.3 0.89 (SE); placebo 6.6 0.86; p 0.42], (2) winmagnitude
(MPH 1213 188; placebo 1041 97; p 0.98), (3) losses in a
round before win (MPH 1.91  0.11; placebo: 2.1  0.08; p 
0.23), and (4) initial round loss (MPH 625 29; placebo 635
25; p  0.65). BIS/BAS subscores did not correlate significantly
with any of these measures (p values0.3).
Choice
Both groups gambled significantlymore than chance (MPH: t(16)
8, p 0.001; placebo: t(19) 6.1, p 0.001), but overall gambling
rates did not differ between groups or vary with BIS/BAS score (p
values  0.36). Likewise, the overall tendency to switch behavior
from the previous choice did not differ between groups (p values
0.5). See Table 1.
The effect of stake
We observed a significant interaction between the effect of
drug group and the effect of stake magnitude (see Table 2).
This effect was due to the absence of stake-induced inhibition
in theMPH group, which was otherwise present in the placebo
group. If looking only at trials that followed a loss induced by
the subject (i.e., removing the first trial of each round from
analysis), the interaction between stake and drug remained
significant (  0.69, z  1.99, p  0.05). Between-group
comparisons showed that the MPH group gambled signifi-
cantly more for 1600 kr stakes (MPH 0.74  0.05; placebo
0.54 0.07; t(35) 2.3, p 0.03) and, as a trend, gambled less
for 200 kr stakes (MPH: 0.71 0.06; placebo 0.84 0.03; t(24)
 1.8, p  0.08) (Fig. 2). Corresponding to multilevel regres-
sion effects of stake, chase value ratio was higher in the MPH
group (t(35) 2.41, p 0.022). Quit value ratios did not differ
significantly between groups (p  0.16). See Table 2.
The effect of accumulated loss
We observed a significant interaction between drug group and
the magnitude of accumulated loss throughout the game. Accu-
mulated loss reduced gambling in the placebo group but had no
effect in the MPH group. See Table 3.
BIS/BAS
We observed a significant interaction effect between trait reward
responsiveness (BAS-R) and stake magnitude on the choice to
gamble. Like MPH treatment, higher reward responsiveness was
associated with reduced influence of stake magnitude on choice
(Table 4). No other BIS/BAS measure had a significant effect;
however, drive (BAS-D) produced a trend interaction effect (p
0.08), reflecting its correlation with reward responsiveness (r 
0.5, p  0.002). Adding a three-way drug  BAS-R  stake
Table 1. General persistencemeasures
Measure
Drug group
Placebo MPH
Mean SD Mean SD
Plays: all choices 0.69 0.14 0.73 0.12
Switches from previous: all choices 0.44 0.16 0.40 0.14
Mean stake Play: mean overall stake 0.87 0.22 1.03 0.15
Mean stake Quit: mean overall stake 1.12 0.41 0.93 0.41
Deliberation time, Play (ms) 1045 296 1329 549
Deliberation time, Quit (ms) 1196 414 1434 500
Money lost (kr) 47,031 16,988 58,843 17,239
Table 2. Effects of stake and drug on choice
 SE Z p z SDRE
Stake drug
Intercept 1.1315 0.1658 6.826 0.00 0.92
Stake (100 kr units) 0.4595 0.2609 1.761 0.08 1.41
Drug: MPH (1) /placebo (1) 0.1387 0.1658 0.837 0.40
Drug stake 0.633 0.2609 2.426 0.015*
MPH
Intercept) 1.24 0.17 7.29 0.00* 0.59
Stake 0.16 0.38 0.43 0.66 1.40
Placebo
Intercept 0.96 0.31 3.04 0.002* 1.34
Stake 1.14 0.44 2.59 0.009* 1.78
*p 0.05.
Figure 2. Interaction of drug and stake on risky persistence. Probability of decision to accept
a double-or-nothing gamble across various magnitudes of stake. Gambling probability was
reduced with increasing stakes in the placebo group but not the MPH group (see Table 2). This
led to a significant difference of gamblingprobability at high stakes (1600 kr). Error bars are1
SE (between subjects). *p 0.05.
Table 3. Effects of game losses and drug on choice
 SE Z p z SDRE
Game losses drug group
Intercept 0.96 0.12 7.8 0.00 0.75
Game losses (1000 kr units) 0.01 0.00 2.4 0.02* 0.00
Drug: MPH (1)/placebo (1) 0.11 0.12 0.86 0.39
Game losses drug 0.01 0.00 2.18 0.03*
MPH
Intercept 1.08 0.15 7.01 0.00 0.55
Game losses 0.00 0.00 0.01 1.00 0.00
Placebo
Intercept 0.84 0.20 4.24 5.06 0.81
Game losses 0.014 0.004 3.38 0.00* 0.00
*p 0.05.
Table 4. Effect of stake and reward responsiveness on choice
 SE z p z SDRE
BASR stake
Intercept 1.12 0.16 6.89 0 0.95
Stake (100 kr units) 0.53 0.25 2.09 0.04* 1.45
BAS-R 0.07 0.11 0.73 0.47
BASR stake 0.48 0.17 2.85 0.004*
*p 0.05.
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interaction effect to the model did not increase its predictive
value and did not produce a significant effect. BAS-R and MPH
appeared to have additive effects on stake influence at this dose.
No BIS/BASmeasures predicted the effect of accumulated loss on
choice. See Table 4.
Deliberation time
Drug groups did not significantly differ on deliberation time, but,
as a trend,MPH subjects tended to take a bit longer tomake their
choice (t(25)  1.8, p  0.08). Deciding to give up took longer
than deciding to gamble (Play: 1175  73 ms; Quit: 1305  76;
F(1,35) 6.2, p 0.02), but this effect did not interact with drug
group (p  0.6). Neither stake nor its interaction with group
influenced deliberation time (p values 0.25). In a model con-
taining the effects of accumulated loss and drug group effects on
deliberation time, however, we did observe a significant main
effect of accumulated loss on deliberation time ( 6, t(8)
3.8, p  0.001) and a trend interaction with drug group ( 
3, t(8)1.74, p 0.07). See Table 1.
Discussion
Both groups gambled significantly more than chance, replicating
previous task performances (Campbell-Meiklejohn et al., 2008,
2011). High stakes increased the likelihood of giving up in the
placebo group but failed to inhibit persistent gambling in the
MPH group. Similarly, only the placebo group gambled less as
assets gradually diminished. These findings could not be ex-
plained by any other measure.
In economics, investing more following a lost investment de-
spite it being apparently unwise to do so is known as an “escala-
tion of commitment” (Staw, 1981, 1996). Descriptive theories of
choice under uncertainty attribute this behavior to the fact that a
tentative loss falls on the convex part of a psychophysical function
relatingmonetary value to its subjective value or utility, such that
the gain of utility associated with recovery is proportionately
greater than the reduction in utility associated with sustaining
another loss (Kahneman and Tversky, 2000). The results of this
study suggest that catecholamine systems mediate the effect of
stake magnitude on this phenomenon, complementing previ-
ously established influences of catecholamine activity on other
decisions (Cools et al., 2006; Zeeb et al., 2009).
While the failure to inhibit riskychoicewithhigh stakes following
MPH treatment makes a novel contribution to our understand-
ing of catecholamine mediation of risky behavior, it also leads to
the question of how this effect occurs. We present a few possibil-
ities. First, one can frame the decision of this task with a simple
model by which choices of a double-or-nothing gamble reflect its
expected value, calculated as follows: [probability of recovery
value of recovered] [probability of further loss value of lost
stake].With an estimated probability of recovery that is0.5, the
expectedvalueof thegamblewill be lower thanaccepting the current
state of affairs. Increasing the stake would enhance this difference
and, therefore, the likelihoodof givingup.However, impairment on
either estimationor applicationof low rewardprobability (respond-
ing as if probability was closer to 0.5), or heightened estimates of
recovery value, could theoretically increase the expected value of the
gamble and counter the inhibiting effect of high stakes.
So, MPH may have countered the effect of high stakes by
impaired adjustment to evidently low reward probability. Sup-
porting this proposal, previous studies of rats have shown that
enhanced catecholamine activity can impair behavioral adjust-
ments to changing outcome probabilities (St Onge and Floresco,
2009; St Onge et al., 2010). Similarly, dopaminergic medication
in Parkinson’s patients can impair behavioral adjustments to
negative outcomes (Cools et al., 2001, 2006; Frank et al., 2004).
The behavior of rats treated with amphetamine suggests a greater
expectancy of reward following near-misses, despite a clear signal
that no reward will occur (Winstanley et al., 2011). In humans,
amphetamine can change neural and affective responses to cues
of upcoming loss to bemore like those of upcoming gains (Knut-
son et al., 2004). In the present study, the MPH group failed to
gradually reduce gambling as more losses were encountered. Al-
though this effect is clearly confounded by time spent playing the
task, itmay have resulted froma failure to learn lowprobability or
adjust behavior accordingly. Such an effect could counter the
effect of high stakes. Yet, both treatment groups also maintained
a high gambling rate throughout the game. Therefore, it was the
case either that neither group accurately learned the low proba-
bility of reward from individual decisions or that this was not the
sole determinant of decisions to gamble and give up.
MPH could have also increased the estimated value of recov-
ery. Persistent gambling after loss is theorized to be influenced by
affective responses to potential outcomes (Lesieur, 1984; Julius-
son, 2006; Campbell-Meiklejohn et al., 2008), and positive affec-
tive responses (e.g., desire, interest, or hunger) to reward cues are
known effects of oral doses of MPH (Volkow et al., 2002, 2004).
Presumably, a greater affective response to a reward indicates
greater subjective value. Support for such an affectivemechanism
comes from our finding that trait reward responsiveness pro-
duces a similar effect on stake-based inhibition to that of MPH.
While the effects of trait reward responsiveness andMPHdid not
interact at this dose (e.g., a ceiling of reward responsiveness may
not have been reached), the common additive effect leaves the
possibility that they share a commonmechanismopen for further
research. A state measure of reward responsiveness to loss recov-
ery before and after treatment would be helpful in this regard. If
confirmed, the fact that the influence of stakemagnitude, but not
the influence of accumulated game loss, is associated with reward
responsiveness would suggest that MPH modulates the two by
separate mechanisms.
MPH may have also affected decisions through effects on
other cognitions. For example, it may have engendered less con-
sideration of declining future opportunities to recover when
stakes were high and resources were limited (a maximum possi-
ble loss). Onemight also suggest thatMPHcaused amore general
effect of increased stereotyped or perseverative behavior, making
the subject generally immune to other influences (Fog, 1969;
Scheel-Kru¨ger, 1972). Randomization of choice-button associa-
tions rules out a simplemotor stereotypy account of the findings,
while a similarity between groups with respect to repeating the
previous choice can rule out a general effect of MPH on choice
stickiness. MPH may have caused stricter adherence to more
complex choice patterns, although such patterns would likely
differ from subject to subject and are difficult to pinpoint. In the
future, it will be worth exploring how the effect of MPH to pre-
vent inhibition by high stakes generalizes to effects on the influ-
ence of other cues. To begin, one could investigate the effect of
MPH on the influence of cues that normally increase gambling,
which is hinted by a trend reduction of gambling at lower stakes,
relative to placebo. Since no clear indications to increase gam-
bling were present in this task, the current results speak only to
diminished inhibition.
The effect of MPH on stake was very similar to the effect
of pramipexole, a direct D2/D3 receptor agonist (Campbell-
Meiklejohn et al., 2011). Like MPH, pramipexole increases stakes
associated with gambling, without affecting overall gambling rates.
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Also in the earlier study, no effect on choice was found by a
-adrenergic receptor blocker, propranolol, making enhanced do-
pamine activity a good candidate for a pharmacologicalmechanism
of MPH effects reported here. The roles of -adrenergic receptors
(Gamo et al., 2010), however, still require formal testing.
Our findings suggest that use of stimulants for “cognitive en-
hancement” by healthy adults may increase their tendency to
persistently take risks despite cues to do otherwise. The results
also strengthen parallels that have been speculatively drawn be-
tween the etiology and effects of problem gambling, abuse of
psychotropic stimulants, and other pharmacological addictions
(Zack and Poulos, 2009; Leeman and Potenza, 2012). For exam-
ple, amphetamine can prime gambling-related cognition and in-
crease the desire to gamble in pathological gamblers (Zack and
Poulos, 2004). One explanation is that dopamine mediates the
intrinsic enjoyment of gambling. However, our findings suggest
that it could also derive from reduced influence by inhibitory
cues, perhaps due to increased responding to potential gains
(Voon et al., 2010). The results also emphasize the importance of
observing the impact of inhibitory cues when examining the re-
lationship between impulse control disorders and dopaminergic
medication.
Future studies may also wish to consider the following. First,
in this study, subjects were informed that the best possible out-
come would not occur by choosing an exclusive choice policy of
playing or quitting. Hypothetically, this instruction may have
nudged subjects away from a preferred normative strategy to
always quit in light of a low gamble success rate (note, however,
consistently high gambling rates provided no indication that sub-
jects would have preferred to exclusively quit). Researchers may
wish to consider excluding this instruction. Second, we used a
competitive game structure for payoffs. This may have caused
subjects to accept more risks than they would have done other-
wise, for the slimpossibility of gaining an edge on other players. It
would be desirable to replicate this effect without the competitive
game structure. Likewise, it would be desirable to test the gener-
alizability of the findings to real monetary outcomes, a variety of
cost types (e.g., effort), real gambling environments, and situa-
tions with full knowledge of declining assets. Finally, despite fe-
male gender being a predictor of impulse control disorder onset
following dopamine agonist treatment (Voon et al., 2011) and
approximately one-third of diagnosed pathological gamblers be-
ing female (Volberg and Steadman, 1988; Bland et al., 1993),
further work is needed establish the effects in males.
Conclusion
Overall, the findings suggest that MPH reduces inhibitory influ-
ences on risky behavior after experiencing a loss, resulting in
more frequent gambling at higher stakes. This is new evidence for
a catecholamine-mediated mechanism determining persistent
risky choice.
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